FDA Recommends Pre-BLA Meeting for Congenital HI, Keeping Salvage Path in Play

What happened

On October 5, 2026, Rezolute announced that the FDA has recommended a Pre-BLA meeting as a precursor to submitting a Biologics License Application for ersodetug in congenital hyperinsulinism, with the agency reiterating its commitment to addressing the unmet need in both congenital and tumor-related HI. This development follows the December 2025 failure of the Phase 3 sunRIZE study, which triggered an ~85% share price collapse and left the congenital program's regulatory future highly uncertain. While the FDA's recommendation to hold a Pre-BLA meeting signals a willingness to discuss the path forward, it does not guarantee that existing data will support approval; the agency may still require an additional confirmatory study. Rezolute also continues to advance the streamlined Phase 3 upLIFT trial in tumor HI, with topline data expected in 2H26, providing a separate potential value driver. Investors should treat the Pre-BLA meeting as a positive but early signal, with material uncertainty remaining until the meeting's outcome and any subsequent trial requirements are disclosed.

Implication

For investors, the FDA's recommendation to hold a Pre-BLA meeting on congenital HI after the sunRIZE failure meaningfully increases the probability that the agency is open to a salvage pathway, potentially using open-label extension data or a finite additional study. However, the Pre-BLA meeting is only a discussion step; the FDA could still insist on a new randomized trial that would strain Rezolute's cash runway beyond mid-2027. The stock's reaction to this news will likely be positive but may overshoot the actual reduction in regulatory risk, as many questions about trial design and endpoint adequacy remain unanswered. Meanwhile, the tumor HI upLIFT trial remains a separate binary event with its own execution and data risks, and the company's cash burn of roughly $70 million annually requires disciplined management. Prudent investors should wait for the Pre-BLA meeting minutes and any FDA feedback on additional requirements before adding exposure, while continuing to monitor upLIFT enrollment and litigation overhang.

Thesis delta

The prior thesis viewed the congenital HI path as entirely speculative with no FDA endorsement of a totality-of-evidence approach. Today's news shifts that stance slightly: the FDA's willingness to hold a Pre-BLA meeting suggests the agency may consider a streamlined BLA based on existing and open-label data, but no details are yet available. This increases the probability of the bull scenario (salvage path) from low to moderate, but does not change the overall wait rating until the meeting outcome and any required additional studies are clarified.